Clinical trials: Triple-Negative Breast Carcinoma
Triple Negative Breast Neoplasms
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease…
- Trial name
- CAPPA (NCT05973864)
- Testing
- Pembrolizumab injection, Capecitabine tablets, Local radiotherapy
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- UNICANCER
Cancer, Melanoma
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune responses, as monotherapy or in combination with…
- Conditions
- Cancer, Melanoma, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT01986426
- Testing
- LTX-315 consecutive lesions, LTX-315, LTX-315 + ipilimumab
- Where
- 14 sites in Belgium, France and 3 more
- Volunteers
- 80 people
- Sponsor
- Lytix Biopharma AS
Triple-Negative Breast Cancer (TNBC)
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer
Cancer is considered a major global public health problem. It was estimated that in 2022 approximately 19.9 million new cancer cases were diagnosed worldwide, and this number is expected to increase over the next two decades to…
- Trial name
- NCT07484776
- Testing
- Cardiovascular training at maximal fat oxidation (FATmax), Cardiovascular training at maximal aerobic power (MAP), Resistance training
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Universidad Europea de Madrid
Breast Cancer
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
This research is being done because the investigators are looking for new and better ways to treat a type of breast cancer called triple negative breast cancer.
- Trial name
- IMpALA (NCT04188119)
- Testing
- Avelumab, Aspirin, Lansoprazole
- Sponsor
- The Christie NHS Foundation Trust
Breast Neoplasm Female, Triple -Negative Breast Cancer
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
This study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in locally…
- Trial name
- NCT07880600
- Testing
- Pre-treatment DCE-MRI-based AI model
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Breast Neoplasms
BRCA Mutations in Latinas
Background: BRCA1 and BRCA2 gene mutations have been linked to a higher risk of developing breast cancer and other cancers, and may be associated with types of breast cancer that are more difficult to treat and more likely to…
- Trial name
- NCT01251900
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
- Trial name
- BATON-BC (NCT01745367)
- Testing
- Tivozanib Hydrochloride, paclitaxel
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose…
- Conditions
- Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
- Trial name
- ASCENT-J02 (NCT05101096)
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 36 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Gilead Sciences
Breast Cancer, Breast Carcinoma
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
Background: Breast cancer is the most common cancer in US women. There are different types of breast cancers; some are aggressive and difficult to treat.
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
- Trial name
- NCT07067138
- Testing
- Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Breast Cancer
S-equol in Women With Triple Negative Breast Cancer
The primary objective of this study is to determine if S-equol, an ER-beta agonist, is effective in decreasing the proliferation rate of triple negative breast cancer.
- Trial name
- NCT02352025
- Testing
- S-equol
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Breast Adenocarcinoma, Invasive Breast Carcinoma
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
This phase II trial studies how well nab-paclitaxel and atezolizumab before surgery work in treating patients with triple negative breast cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or…
- Conditions
- Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
- Trial name
- NCT02530489
- Testing
- Atezolizumab, Nab-paclitaxel
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and…
- Trial name
- NCT04265872
- Testing
- Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Metastatic Triple-Negative Breast Cancer
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
Recent progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies including breast cancer. It has been shown that levels of certain cytokines were correlated with increased response to immunotherapy…
- Trial name
- NCT04250818
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Triple Negative Breast Cancer, Triple-Negative Breast Cancer
Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a personalized polyepitope DNA vaccine strategy. The personalized polyepitope DNA vaccines will be formulated as naked plasmid DNA vaccines.
- Conditions
- Triple Negative Breast Cancer, Triple-Negative Breast Cancer, Triple Negative Breast Neoplasms
- Trial name
- NCT02348320
- Testing
- Personalized polyepitope DNA vaccine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Colorectal Neoplasms, Colorectal Cancer
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly…
- Conditions
- Colorectal Neoplasms, Colorectal Cancer, Breast Cancer, Breast Neoplasms
- Trial name
- REFLECT (NCT02732860)
- Testing
- Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc